Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 2,501–2,600 of 4,275
Aging, longevity, and the role of environmental stressors: a focus on wildfire smoke and air quality
Scieszka, D. P., Bolt, A. M., McCormick, M. A., Brigman, J. L., & Campen, M. J. (2023) · Frontiers in Toxicology · doi:10.3389/ftox.2023.1267667 · Cited by 16
Evasion of oncogene-induced senescence by gammaherpesviruses
Leidal, A. M., Pringle, E. S., & McCormick, C. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.09.009 · Cited by 13
Chen, Y., Wu, C., Zhao, X., Tan, H., Li, C., Deng, Y., Chen, X., Wu, Y., Tian, N., Zhang, X., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115865 · Cited by 14
Anwar, T., Sen, B., Aggarwal, S., Nath, R., Pathak, N., Katoch, A., Aiyaz, M., Trehanpati, N., Khosla, S., & Ramakrishna, G. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26227 · Cited by 14
Mitochondria in cell senescence: A Friend or Foe?
Chen, Q., Young, L. H., & Barsotti, R. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.02.019 · Cited by 15
Snake venoms promote stress‐induced senescence in human fibroblasts
Lewińska, A., Bocian, A., Petrilla, V., Adamczyk‐Grochala, J., Szymura, K., Hendzel, W., Kaleniuk, E., Hus, K. K., Petrillová, M., & Wnuk, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27382 · Cited by 14
“As genotoxic agents may promote cellular senescence and genomic instability is one of the features of cellular senescence (Campisi & d’Adda di Fagagna, 2007; Kuilman et al., 2010; McHugh & Gil, 2018; Sikora et al., 2011), we have also evaluated if snake venoms with prosenescent activity may affect genomic stability an…”
BackgroundInfluentialRegulation of cellular senescence by innate immunity
Hou, J., Zheng, Y., & Gao, C. (2023) · Biophysics Reports · doi:10.52601/bpr.2023.230032 · Cited by 18
“IFN-I can engage in p53 signals, and the important role p53 plays is initiating senescence from growth arrest, but p53 is not necessary for the secretion of SASP (Coppe et al. 2008), which is exactly the stage where IFN-I comes into play.”
BackgroundHuman iPSC-Derived Neurons as A Platform for Deciphering the Mechanisms behind Brain Aging
Chao, C., Shen, P.-W., Tzeng, T., Kung, H., Tsai, T., & Wong, Y. (2021) · Biomedicines · doi:10.3390/biomedicines9111635 · Cited by 14
Yang, Y., Duan, C., Huang, L., Xia, X., Zhong, Z., Wang, B., Wang, Y., & Ding, W. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112838 · Cited by 13
Regulation of cell function and identity by cellular senescence
Huna, A., Massemin, A., Makulyte, G., Flaman, J., Martin, N., & Bernard, D. (2024) · The Journal of Cell Biology · doi:10.1083/jcb.202401112 · Cited by 14
A novel suicide gene therapy for the treatment of p16Ink4a-overexpressing tumors
Kohli, J. S., Campisi, J., & Demaria, M. (2017) · Oncotarget · doi:10.18632/oncotarget.23752 · Cited by 14
“Cells were transduced with lentiviruses expressing RASVal12, p53-GSE or control particles, as previously described [21].”
MethodSelf-citationLiu, H.-Y., Chang, C., Lu, C., Wu, S., Huang, B., Cheng, T., Lin, S., Ho, C.-J., Lee, M., Yang, C., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071477 · Cited by 18
“Senescent cells, which are cell-cycle arrested, are actually metabolically active and associated with the overproduction of cytokines (e.g., interleukins 1 and 6), growth factors (e.g., epidermal growth factor, transforming growth factor β), as well as matrix-degrading enzymes such as the MMPs (e.g., MMP-3, MMP-13), c…”
BackgroundInfluentialDetecting Senescence: Methods and Approaches
Crowe, E. P., Nacarelli, T., Bitto, A., Lerner, C. A., Sell, C., & Torres, C. A. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0888-2_23 · Cited by 14
Chatterjee, D., & Chakrabarti, O. (2021) · International Journal of Cancer · doi:10.1002/ijc.33787 · Cited by 13
“of senescent cells is different from its nonsenescent counterparts, being both enlarged and flattened in shape.(34) This suggests that major rearrangements of the cytoskeleton must play a pivotal role in bring-”
BackgroundZhou, Y., Xiao, L., Long, G., Cao, J., Liu, S., Tao, Y., Zhou, L., & Tang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.921182 · Cited by 18
“The multivariate analysis demonstrates that SASP Frontiers in Immunology 14 positivity is an independent prognostic factor in both luminal A IBC and TNBC (27).”
BackgroundInfluentialHe, M., & Borlak, J. T. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00373-5 · Cited by 15
Senescence and Immunotherapy: Redundant Immunomodulatory Pathways Promote Resistance
Oesterreich, S., & Aird, K. M. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0051 · Cited by 15
Drullion, C., Marot, G., Martin, N., Deslé, J., Saas, L., Salazar-Cardozo, C., Bouali, F., Pourtier, A., Abbadie, C., & Pluquet, O. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.008 · Cited by 19
McDonald, J. T., Gao, X., Steber, C. R., Breed, J. L., Pollock, C., Ma, L., & Hlatky, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178155 · Cited by 15
The crucial roles and research advances of cGAS‑STING pathway in liver diseases
Zhang, X., He, B., Lu, J., Bao, Q., Wang, J., & Yang, Y. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2394588 · Cited by 15
“Recent research has highlighted several additional roles of senescence, which involve the production of assorted inflammatory agents such as chemokines, growth factors, and interleukins, collectively recognized as the senescence-associated secretory phenotype (SASP) [38,39].”
BackgroundSarangi, U., Paithankar, K. R., Kumar, J. U., Subramaniam, V., & Sreedhar, A. S. (2012) · Drug Target Insights · doi:10.4137/dti.s9943 · Cited by 16
Wnuk, M., Sol‐Fernández, S. D., Błoniarz, D., Słaby, J., Szmatoła, T., Żebrowski, M., Martínez‐Vicente, P., Litwinienko, G., Moros, M., & Lewińska, A. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c00771 · Cited by 14
Is Evidence Supporting the Subtelomere–Telomere Theory of Aging?
Libertini, G., Shubernetskaya, O., Corbi, G., & Ferrara, N. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921120026 · Cited by 21
Targeting Cellular Senescence: Pathophysiology in Multisystem Age-Related Diseases
Liu, J., Yu, H., & Xu, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13071727 · Cited by 15
“Microglia from aged mice produce large quantities of proinflammatory cytokines IL-6, IL-1 β , and TNF-α [121], which are significantly upregulated in senescent cells [122].”
From bench to bedside: The critical need for standardized senescence detection
Shah, J., Al-Hashimi, A., Benedetto, M., & Ruchaya, P. J. (2025) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2024.12.008 · Cited by 13
Anti-aging mechanism of different age donor-matched adipose-derived stem cells
Wang, T., Li, Y., Zhu, Y., Liu, Z., Huang, L., Zhao, H., Zhou, Z., & Wu, Q. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03415-3 · Cited by 15
“IL-1β, IL-6, and TNF-α are classical proinflammatory cytokines associated aging and obesity [6, 16, 23], the levels of IL-1β, IL-6, and TNF-α in serum were significantly decreased in the Y-ASC transplantation group when compared to the old control group.”
BackgroundCarroll, J., Olmstead, R. E., Cole, S. W., Breen, E. C., Arevalo, J. M. G., & Irwin, M. R. (2023) · GeroScience · doi:10.1007/s11357-023-00741-5 · Cited by 15
Acosta, J. C., Snijders, A. P., & Gil, J. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-239-1_11 · Cited by 13
Rejuvenation of Senescent Cells, In Vitro and In Vivo, by Low‐Frequency Ultrasound
Kureel, S. K., Maroto, R., Aniqua, M., Powell, S. N., Singh, E., Margadant, F., Blair, B., Rasmussen, B. B., & Sheetz, M. P. (2025) · Aging Cell · doi:10.1111/acel.70008 · Cited by 15
“An increase in the level of SASP catalyzes many age-related problems (Coppe et al. 2008; da Silva et al. 2019).”
Li, Y., Zhang, C., Cheng, H., Lv, L., Zhu, X., Ma, M., Xu, Z., He, J., Xie, Y., Yang, X., et al. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112522 · Cited by 14
Dehghan, N., Mousavikia, S. N., Qasempour, Y., & Azimian, H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123218 · Cited by 16
Cellular Senescence in Liver Cancer: How Dying Cells Become “Zombie” Enemies
Gazzillo, A., Volponi, C., Soldani, C., Polidoro, M. A., Franceschini, B., Lleò, A., Bonavita, E., & Donadon, M. (2023) · Biomedicines · doi:10.3390/biomedicines12010026 · Cited by 15
MAPKs in the early steps of senescence implemEMTation
Anerillas, C., Altés, G., & Gorospe, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1083401 · Cited by 13
“This antagonism is in keeping with the existence of a balance between competing signaling pathways in other aspects in senescence (Coppe et al., 2008; Hoare et al., 2016).”
BackgroundThe effects of macronutrients metabolism on cellular and organismal aging
Nehme, J., Altulea, A., Gheorghe, T., & Demaria, M. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.02.005 · Cited by 16
“Additionally, p53 suppresses several components of the SASP [6], suggesting that the SASP might be regulated, in part, by glycolysis.”
BackgroundInfluentialPeropadre, A., Freire, P. F., & Hazen, M. J. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.09.020 · Cited by 13
Anti-Cancer Role and Therapeutic Potential of Extracellular Vesicles
Tominaga, N. (2021) · Cancers · doi:10.3390/cancers13246303 · Cited by 13
Cellular Senescence-Inducing Small Molecules for Cancer Treatment
Liu, P., Lu, Z., Wu, Y., Shang, D., Zhao, Z., Shen, Y., Zhang, Y., Zhu, F., Liu, H., & Tu, Z. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009618666180530092825 · Cited by 12
Zhou, L., Zeng, Y., Liu, Y., Du, K., Luo, Y., Dai, Y., Pan, W., Zhang, L., Zhang, L., Tian, F., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12234-5 · Cited by 12
“Cellular senescence is a frequently observed phenomenon characterized by a state of irretrievable growth arrest in cells, characterized by alterations in cell structure and function, as well as the induction of a senescence-associated secretory phenotype (SASP) [28, 29].”
BackgroundCellules souches mésenchymateuses: Production à usage clinique et contraintes sécuritaires
Sensebé, L., & Bourin, P. (2011) · médecine/sciences · doi:10.1051/medsci/2011273297 · Cited by 20
Effect of Aging and Sex on Circulating MicroRNAs in Humans
Sawada, S., Akimoto, T., Takahashi, M., Sakurai, R., Shinkai, S., Ushida, T., Fujiwara, Y., & Suzuki, K. (2014) · Advances in Aging Research · doi:10.4236/aar.2014.32023 · Cited by 12
“Recent studies have shown that senescent cells triggered secrete various factors such as proinflammatory cytokines and chemokines [43]-[46].”
BackgroundTelomerase regulation and the intimate relationship with aging
Morgan, G. (2013) · Research and Reports in Biochemistry · doi:10.2147/rrbc.s28603 · Cited by 15
An antibiotic that mediates immune destruction of senescent cancer cells
Raffi, G. C., Chen, J., Feng, X., Chen, Z., Lieftink, C., Deng, S., Mo, J., Zeng, C., Steur, M., Wang, J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2417724121 · Cited by 17
Cellular senescence and tumor promotion: Role of the Unfolded Protein Response
Pluquet, O., & Abbadie, C. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.01.001 · Cited by 13
Noh, B., Blasco-Conesa, M. P., Lai, Y., Ganesh, B. P., Urayama, A., Moreno‐González, I., Marrelli, S. P., McCullough, L. D., & Moruno-Manchon, J. F. (2022) · Frontiers in Aging · doi:10.3389/fragi.2021.797562 · Cited by 14
Role of the Hypoxic-Secretome in Seed and Soil Metastatic Preparation
Clemente-González, C., & Carnero, A. (2022) · Cancers · doi:10.3390/cancers14235930 · Cited by 14
The cGAS/STING signaling pathway: a cross-talk of infection, senescence and tumors
Zeng, P.-H., & Yin, W.-J. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2109899 · Cited by 15
Wang, N., Fang, Y., Hou, Y., Cheng, D., Dressler, E. V. M., Wang, H., Wang, J., Wang, G., Li, Y., Liu, H., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01861-x · Cited by 21
“Among the SASP factors (GRO-α,- β,-γ, GM-CSF, IL-7, MCP-2, IL-13, ICAM-3, TRAIL-R3, Fas/TNFRSF6, IGFBP-6, and bFGF) secreted by BJ cells induced to undergo senescence by 20% oxygen [18], GM-CSF [19–22], bFGF [23–27] and CXCL1 [28–32] have been reported to promote cell migration.”
BackgroundFotopoulou, A., Angelopoulou, M. T., Pratsinis, H., Mavrogonatou, E., & Kletsas, D. (2024) · Aging Cell · doi:10.1111/acel.14422 · Cited by 15
“Senescent cells express a distinctive pro-inflammatory and catabolic phenotype, called the “senescence-associated secretory phenotype” (SASP) affecting tissue homeostasis (Coppé et al., 2008; Gorgoulis et al., 2019; Mavrogonatou et al., 2023).”
Tackling cellular senescence by targeting miRNAs
Wang, Z., Gao, J., & Xu, C. (2022) · Biogerontology · doi:10.1007/s10522-022-09972-z · Cited by 15
Bang, E., Lee, B., Noh, S., Kim, D. H., Jung, H. J., Ha, S., Yu, B. P., & Chung, H. Y. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.301 · Cited by 12
“by DNA damage, replicative exhaustion, and oncogenic stimuli in keratinocytes, melanocytes, monocytes, fibroblasts, and epithelial cells (10-12).”
BackgroundIdentification of p38 MAPK as a novel therapeutic target for Friedreich’s ataxia
Cotticelli, M. G., Xia, S. J., Kaur, A., Lin, D., Wang, Y., Ruff, E., Tobias, J. W., & Wilson, R. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-23168-x · Cited by 13
Papadopoulou, A., Kalodimou, V. E., Mavrogonatou, E., Καραμάνου, Κ., YIACOUMETTIS, A. M., Panagiotou, P. N., Pratsinis, H., & Kletsas, D. (2022) · IUBMB Life · doi:10.1002/iub.2659 · Cited by 12
“These pro-inflammatory molecules are considered as important SASP constituents that can influence immune, tumor, and stromal cells.(61,62) Expression of pro-inflammatory molecules by adipose cells and ASCs has already been reported to be implicated in a pro-tumorigenic PAPADOPOULOU ET AL.”
BackgroundAifuwa, I., Kim, B. C., Kamat, P., Starich, B., Agrawal, A., Tanrioven, D., Luperchio, T. R., Valencia, A. M. J., Perestrelo, T., Reddy, K. L., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac270 · Cited by 13
“Under certain conditions, when damage is irreparable, cells halt their progress through the cell cycle to limit the perpetuation of cellular damage (9, 10).”
BackgroundAtrophied Thymus, a Tumor Reservoir for Harboring Melanoma Cells
Sizova, O. S., Kuriatnikov, D., Liu, Y. M., & Su, D. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0308 · Cited by 13
“In addition, senescent stromal cells could promote an epithelial-to-mesenchemal transition (38), which establishes a condition for cancer stem cell generation and cancer metastasis.”
BackgroundZhang, Z., He, X., Sun, Y., Li, J., & Sun, J. (2025) · Aging and Disease · doi:10.14336/ad.2025.0233 · Cited by 35
“SASP drives chronic disease progression by altering tissue environments and transmitting senescence signals [156].”
Self-citationCell-based immunomodulatory therapy approaches for type 1 diabetes mellitus
Black, L. A., & Zorina, T. D. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.016 · Cited by 13
Cancer research: A hurdle race
Lichtenstein, A. V. (2014) · Biochemistry (Moscow) · doi:10.1134/s0006297914050010 · Cited by 12
Is Myelodysplasia a Consequence of Normal Aging?
Heibl, S., Stauder, R., & Pfeilstöcker, M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01136-5 · Cited by 17
PROTGOAT : Improved automated protein function predictions using Protein Language ModelsPreprint
Chua, Z. M., Rajesh, A., Sinha, S., & Adams, P. D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.01.587572 · Cited by 12
Liu, Q., Song, Y., Cui, Y., Hu, C., Luo, Y., Hu, D., Wang, H., Li, K., Chen, J., & Xiao, H. (2021) · SSRN Electronic Journal · doi:10.1016/j.biocel.2022.106343 · Cited by 11
Ponnusamy, S., Amin, M., Bhat, A. G., Garczynski, S., Rahman, S. U., Rasam, S. S., Govindool, S. R., Khan, I., & Arany, P. R. (2026) · Cells · doi:10.3390/cells15010088 · Cited by 15
“The elucidation of the senescence-associated secretory phenotype (SASP) involving key inflammatory cytokines suggests that it contributes to one of the putative mechanisms of cellular senescence that has been termed inflammaging [44,45].”
Senescence of skeletal stem cells and their contribution to age-related bone loss
Wölfel, E. M., Guerra, P. F., Nørgård, M. Ø., Jeromdesella, S., Kjær, P. K., Elkjaer, A. S., Kassem, M. S., & Figeac, F. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111976 · Cited by 16
Natural Products in Aging: Cellular Mechanisms and Emerging Therapeutics for Age‐Related Disorders
Dixit, V., Chaubey, K. K., Dayal, D., Chole, P. B., Manjunath, B. T., Bachheti, R. K., Gupta, P. C., Bachheti, A., & Worku, L. A. (2025) · Journal of Aging Research · doi:10.1155/jare/6868732 · Cited by 12
“T e l o m e r e d y s f u n c t i o n - i n d u c e d p r o t e i n s , b l oo d l e u k o c y t e - d e r i v e d t e l o m e r e l e n g t h [ 120 ] E p i g e n e t i c a l t e r a t i o n”
Banda, M., Recio, L., & Parsons, B. L. (2013) · Environmental and Molecular Mutagenesis · doi:10.1002/em.21808 · Cited by 12
“MAPK pathway activation can cause a proliferative effect; however, relatively strong, long duration MAPK signaling can induce the DNA damage response, oncogene induced senescence, and or non-apoptotic cell death [Coppe et al., 2008; Mates et al., 2008; Hu et al., 2011; Shaw et al., 2011].”
BackgroundHwang, H. J., Jung, S. H., Lee, H., Han, N. K., Bae, I. H., Lee, M., HAN, Y.-H., Kang, Y., LEE, S.-J., Park, H. J., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.4473 · Cited by 14
“The major factors secreted by senescent cells are inflammatory cytokines, chemokines, growth factors, matrix metalloproteinases, and their inhibitors, such as IL-1, IL-6, IL-8, GRO, MCP-1, VEGF, MMP-1, MMP-3, MMP-10 and PAI (34,36).”
BackgroundFlorido, R., Tchkonia, T., & Kirkland, J. L. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-378638-8.00005-1 · Cited by 17
Cellular senescence is a double‐edged sword in regulating aged immune responses to influenza
Torrance, B. L., Panier, H. A., Cadar, A. N., Martin, D., Lorenzo, E. C., Jellison, E. R., Bartley, J. M., & Haynes, L. (2024) · Aging Cell · doi:10.1111/acel.14162 · Cited by 11
“Therefore, our results suggest that p16-expressing cells play a key role, perhaps through one or more SASP factors, in fostering the effector to memory transition in CD8 T cells.”
BackgroundInfluentialThe Effects of IL-1β on Astrocytes are Conveyed by Extracellular Vesicles and Influenced by Age
Willis, C. M., Sutter, P. A., Rouillard, M. E., & Crocker, S. J. (2020) · Neurochemical Research · doi:10.1007/s11064-019-02937-8 · Cited by 12
Sugimoto, Y., Okamoto, K., Saito, H., Yamaguchi, T., Kinoshita, J., Nakamura, K., Takino, T., Endo, Y., Ninomiya, I., Ohta, T., et al. (2024) · Oncology Reports · doi:10.3892/or.2024.8788 · Cited by 13
“Although cellular senescence is considered to be involved in tissue repair and immune cell migration, it is also considered to be involved in the promotion of carcinogenesis and the development of age‑related diseases through the action of SASP (1).”
BackgroundHom, L. M., Sun, S., Campbell, J., Liu, P., Culbert, S., Murphy, I. M., & Schafer, Z. T. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104922 · Cited by 11
“6 Results Conditioned media from senescent fibroblasts promotes caspase-dependent cell death in non-cancerous mammary epithelial cells In order to study the effects of the senescence-associated secretory phenotype (SASP) in fibroblasts on the viability of non-cancerous mammary epithelial cells, we first induced senesc…”
BackgroundCell Sorting of Young and Senescent Cells
Hewitt, G., von Zglinicki, T., & Passos, J. F. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-556-9_4 · Cited by 12
Proteomic Insights into Senescence of Testicular Peritubular Cells from a Nonhuman Primate Model
Stöckl, J. B., Schmid, N., Flenkenthaler, F., Drummer, C., Behr, R., Mayerhofer, A., Arnold, G. J., & Fröhlich, T. (2020) · Cells · doi:10.3390/cells9112498 · Cited by 13
“, fibronectin, laminins, collagens, and MIF, also imply a senescence-associated secretory phenotype (SASP) affecting testicular signaling [25,71].”
BackgroundSenescence-Derived Extracellular Molecules as Modulators of Oral Cancer Development: A Mini-Review
Parkinson, E. K., James, E. L., & Prime, S. S. (2015) · Gerontology · doi:10.1159/000440954 · Cited by 16
Elucidating Proteoform Dynamics Underlying the Senescence Associated Secretory Phenotype
Doubleday, P. F., Fornelli, L., & Kelleher, N. L. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00739 · Cited by 14
Huang, Y., Ge, M.-X., Li, Y.-H., Li, J.-L., Yu, Q., Xiao, F.-H., Ao, H.-S., Yang, L.-Q., Li, J., He, Y., et al. (2022) · Aging and disease · doi:10.14336/ad.2022.1217 · Cited by 12
“SASP factors are primarily regulated by transcription [79].”
BackgroundMaeda, C., & Tsuruta, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084443 · Cited by 13
“The SASP is an important characteristic of senescent cells and releases numerous cytokines and chemokines associated with inflammation [17].”
BackgroundChen, Y., Jiang, F., Kong, G., Yuan, S., Cao, Y., Zhang, Q., Wang, Q., & Liu, L. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9926284 · Cited by 14
Cellular Senescence Exacerbates Features of Aging in the Eyes
Kitazawa, K., Campisi, J., Numa, K., Patel, S. K., King, C. D., Matsumoto, A., Sotozono, C., Desprez, P., & Schilling, B. (2023) · doi:10.59368/agingbio.20230014 · Cited by 14
Self-citationNavitoclax improves acute‐on‐chronic liver failure by eliminating senescent cells in mice
Watanabe, Y., Abé, H., Kimura, N., Arao, Y., Ishikawa, N., Yuichiro, M., Setsu, T., Sakamaki, A., Kamimura, H., Yokoo, T., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13879 · Cited by 14
Recent Advances in Progresses and Prospects of IL-37 in Central Nervous System Diseases
Li, X., Yan, B., Du, J., Xu, S., Liu, L., Pan, C., Kang, X., & Zhu, S. (2022) · Brain Sciences · doi:10.3390/brainsci12060723 · Cited by 17
“Aging tissue cells secrete inflammation and immune-related cytokines, such as interleukins, chemokines, growth factors, and proteases, which constitute senescenceassociated secretory phenotype (SASP) [64].”
BackgroundInterleukin-1 signaling in solid organ malignancies
Dosch, A. R., Singh, S. P., Nagathihalli, N. S., Datta, J., & Merchant, N. B. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188670 · Cited by 15
Honoki, K., & Tsujiuchi, T. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.820010 · Cited by 13
Developing senescence to remodel the embryo
Storer, M. A., & Keyes, W. M. (2014) · Communicative & Integrative Biology · doi:10.4161/cib.29098 · Cited by 14
Stromal senescence contributes to age-related increases in cancer
Ye, J., Melam, A., & Stewart, S. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00840-9 · Cited by 17
“Although there are some overlapping SASP factors expressed between different cell types, the vast majority of reported SASP factors are highly cell-type-dependent even under the same senescence inducer 53 .”
Cellular senescence in metastatic prostate cancer: A therapeutic opportunity or challenge (Review)
Jin, C., Liao, S., Lu, G., Geng, B. D., Ye, Z., Xu, J., Ge, G., & Yang, D. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13286 · Cited by 15
“P53 is a key regulator of SaSP expression (22,69).”
BackgroundInfluences of circulatory factors on intervertebral disc aging phenotype
Lei, C., Colangelo, D., Patil, P. R., Li, V., Ngo, K., Wang, D., Dong, Q. D., Yousefzadeh, M. J., Lin, H., Lee, J., et al. (2020) · Aging · doi:10.18632/aging.103421 · Cited by 12
“Cellular senescence is characterized by persistent genomic damage, growth arrest, and a senescenceassociated secretory phenotype (SASP) comprised of pro-inflammatory cytokines and matrix metalloproteinases (MMPs) that can have profound impact on neighboring cells and the disc matrix [10, 11].”
BackgroundWang, Y., Yu, S., Wang, X., Han, B., Zhao, F., Zhu, G., Hong, Y., & Xia, S. (2011) · Asian Journal of Andrology · doi:10.1038/aja.2011.11 · Cited by 14
Pan, P., Cao, S., Gao, H. Y., Qu, X., Ma, Y., Yang, J., Pei, X., & Yang, Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142368 · Cited by 21
Molecular Pathways: Comparing the Effects of Drugs and T Cells to Effectively Target Oncogenes
Anders, K., & Blankenstein, T. J. F. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3017 · Cited by 12
Zaarour, R. F., Prasad, P., Venkatesh, G. H., Khouzam, R. A., Amirtharaj, F., Zeinelabdin, N. A., Rifath, A., Terry, S., Nawafleh, H. H., Elsayed, Y., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.7938 · Cited by 14
“IL-6 and IL-1β are also found to be senescence-associated secreted factors (44).”
BackgroundTherapy-induced senescence in breast cancer: an overview
Narayanan, C. S., & Lindsay, A. J. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00254 · Cited by 15
Treating Senescence like Cancer: Novel Perspectives in Senotherapy of Chronic Diseases
Mongelli, A., Atlante, S., Barbi, V., Bachetti, T., Martelli, F., Farsetti, A., & Gaetano, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217984 · Cited by 13
“Patients will be evaluated for SASPs and other inflammatory biomarkers integrated with magnetic resonance and physical performance (ClinicalTrial identifier NCT04210986).”
BackgroundInfluentialDNA damage, inflammation and aging: Insights from mice
Arvanitaki, E. S., Stratigi, K., & Garinis, G. A. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.973781 · Cited by 17
“Senescent cells with chromatin hallmarks of irreparable DSBs secrete a wide range of senescence-associated secretory phenotype (SASP) factors, including inflammatory cytokines and chemokines as well as growth factors and extracellular matrix remodeling enzymes (Coppe et al., 2008; Ohanna et al., 2011; Acosta et al., 2…”
BackgroundGenome jail-break triggers lockdown
Umbreit, N. T., & Pellman, D. S. (2017) · Nature · doi:10.1038/nature24146 · Cited by 13
Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence
Fan, Z., Tong, Y., Yang, Z., Wang, S., Huang, T., Yang, D., Ni, Q., Zhang, M., Li, D., Yang, M., et al. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112359 · Cited by 14
Role of Neutrophils in Homeostasis and Diseases
Chang, X., Liu, Y., Qiu, J., & Hua, K. (2025) · MedComm · doi:10.1002/mco2.70390 · Cited by 16
Modelling the dynamics of senescence spread
Martin, L., Schumacher, L. J., & Chandra, T. (2023) · Aging Cell · doi:10.1111/acel.13892 · Cited by 11
“…cell, including large-scale chromatin rearrangement and the production of secretory proteins which can induce senescence in nearby cells (the SASP, senescence associate secretory phenotype)(Acosta et al., 2008; Basisty et al., 2020; Coppé et al., 2008; Kuilman et al., 2008; Narita et al., 2003).”
BackgroundA new model and precious tool to study molecular mechanisms of macrophage aging
Smith, R., Bassand, K., Dussol, A., Piesse, C., Duplus, E., & Hadri, K. E. (2024) · Aging · doi:10.18632/aging.206124 · Cited by 21
“Finally, senescent cells are also characterized by a pro-inflammatory secretome called SASP, composed of chemokines, cytokines, matrix metalloproteases and other components [16].”
BackgroundSenescent Cells: Dual Implications on the Retinal Vascular System
Habibi-Kavashkohie, M. R., Scorza, T., & Oubaha, M. (2023) · Cells · doi:10.3390/cells12192341 · Cited by 13
“The SASP profile of SCs varies, depending on the cell type and the type of inducer [55,56].”
Background
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.